Investor Relations

Cameron is an experienced entrepreneurial executive, with expertise in biotechnology companies. He has extensive experience in the management, structuring, and strategic planning of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, and Non-Executive Director of public and private enterprises.

Cameron was educated at the University of Western Australia receiving both a Bachelor of Commerce and an MBA.

Mr. Hughes is a seasoned finance professional with over twenty-five years of accounting, finance and business management experience gained through an international career spanning the United States, Europe and Asia and joins Volition from AUM Biosciences Pte. Ltd., a fast-growing biotechnology company focused on developing novel cancer drugs, where he acted as Chief Financial Officer since 2018. Prior to then, Mr. Hughes held a number of senior leadership positions at Elsevier, a division of RELX Group plc, a FTSE 100 company, including regional Managing Director and regional Finance Director for Elsevier Health Solutions. He has extensive experience in financial reporting, planning & analysis, and profit and loss management, as well as product commercialization, licensing and distributor management.

Mr. Hughes holds a Bachelor's degree in Accounting and Law from De Montfort University, Leicester, UK.

Dr. Gaetan Michel has been with Volition almost seven years, previously serving as Chief Operating Officer of Belgian Volition and currently as Chief Executive Officer of Belgian Volition. With over 15 years of project management, manufacturing and operational experience, Dr. Michel is ideally placed to oversee and expand Volition's global operations including the newly opened Innovation Hub in San Diego, the manufacturing facility "Silver One" and Research and Development Facility in Belgium, as well as expanding the veterinary subsidiary in Texas, U.S.A.

Jake is an experienced scientist with expertise in research and development and in the management of early stage biotechnical companies, including the manufacturing of biotechnology products and the establishment of manufacturing operations. Jake received his BSc in Biology and Chemistry, and his PhD in Physical Chemistry from King’s College London. In addition, he received his MSc in Chemical Pathology from St Thomas’ Hospital Medical School, and his MBA from Imperial College Management School.

Louise brings more than 20 years of marketing, sales and leadership experience to her role at Volition. Since 2011, she has served as Director and Owner of Aculd Ltd, a strategic marketing consultancy specializing in healthcare. Formerly Louise worked in various roles at Reckitt Benckiser including some overseas posts in Paris and New York. She holds a Bachelor of Arts in Business Studies from Sheffield Hallam University.

Mr. Gael Forterre has over 15 years of experience investing in and scaling fast growing companies. Mr. Forterre started his career as a hedge fund analyst in Paris and worked in a number of investment banking and trading roles over ten plus years, including launching Armori Capital Management LLC in 2014, for which he conducted a large number of investments on behalf of family offices/institutional investors and became active in supporting the growth of its portfolio companies. Most recently, from 2017 until joining Volition, he served as the Chief Executive Officer of Ucroo Incorporated, a fast-growing collaboration and communication technology company, which he led to a tripling in revenue growth two years in a row. Mr. Forterre continues to serve as a board member of Ucroo Incorporated and Article22.

Mr. Forterre holds a Master's degree in finance from Sorbonne Paris I and a double MBA from Columbia Business School and the London Business School.

Jasmine has a proven track record in achieving positive business results by developing strategic business alliances, identifying new markets, and developing business processes. As a thought leade in technology management and commercialization, she has worked with numerous health and regulatory bodies across Asia and has successfully comercialised technologies and expanded companies into the Asian markets.

Jasmine has a Bachelor of Engineering and a Doctor of Philosophy in Oceanography from the National University of Singapore.

Tom Butera is a Doctor of Veterinary Medicine with more than 40 years of experience in equine and small animal health in private practice as well as extensive work in both business development and management of veterinary companies. Since 2016, he has been actively involved in business development roles with Mars Veterinary Health, leading divisions including Pet Partners, LLC, Banfield Pet Hospitals and Veterinary Centers of America (VCA). In his time with Mars, Dr. Butera has been instrumental in the acquisition of more than 60 small animal general practices and specialty/ER hospitals. Prior to joining Mars, Dr. Butera served as Co-Founder, Board Member and Chief Medical Officer of Pet Partners, LLC, an entity that owned and operated 68 small animal veterinary hospitals in 32 states in the U.S., employing approximately 450 veterinarians and 3,200 employees. Dr. Butera’s veterinary business acumen was key to solidifying and growing Pet Partners’ development pipeline, which ultimately positioned the company for overall sale to the Mars Veterinary Health family in April, 2016.

Dr. Butera earned his Doctor of Veterinary Medicine from the University of Missouri Veterinary School, going on to serve as an Assistant Professor at Tufts University Veterinary School heading the large animal anesthetic department for several years. Dr. Butera is an honorary member of the American Veterinary Medical Association and a licensed veterinarian in the Commonwealth of Massachusetts.

Rod is an experienced legal and corporate secretary with over ten years’ experience in providing corporate, legal and administrative services to start-up companies. He previously served as corporate secretary for several junior mining companies in the United Kingdom. Rod received a Bachelor of Laws degree from the University of Western Australia.

Nick is the Group General Counsel of Volition and joined the company in November 2021. He has over 25 years’ experience as a corporate and commercial lawyer, specializing in healthcare. Nick qualified with the international law firm, Ashurst, and has since worked in-house for companies such as Ark Therapeutics PLC and Patheon, which is part of Thermo Fisher Scientific. Nick joined Volition from Novacyt, the Anglo-French AIM listed diagnostic company, where he managed the legal function.

Andrew is Chief Medical Officer at Volition and an intensive care consultant at Guy’s and St. Thomas’ Hospital in London. Dr Retter obtained his medical degree from St. George’s Hospital Medical School in 2001 and completed his postgraduate training in hematology and intensive care medicine at St. Thomas’ Hospital in London. He has subsequently worked as a consultant at St. Bartholomew’s Hospital before joining the team at Guy’s and St. Thomas’ Hospital.

Throughout his career, Andrew has been passionate about using the latest technologies and innovations to improve patient outcomes. He has been involved in clinical trials and research studies and has published over 50 articles in peer-reviewed medical journals. Andrew’s areas of expertise include the management of hematological malignancies and the management of complex coagulopathies, anticoagulation, and sepsis. In addition to his clinical work, Dr Retter is also an accomplished educator and mentor. He teaches and trains medical students, residents, and fellows, and has served as a faculty member for educational courses.